Please login to the form below

Not currently logged in
Email:
Password:

Qtern

This page shows the latest Qtern news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Among the other highlights from the CHMP meeting was the withdrawal by AstraZeneca (AZ) of an application to market diabetes combination Qtern (saxagliptin/dapagliflozin).

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    AZ gets US approval for diabetes combo Qtern. Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015.

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    EU clears AZ's FDA-rejected diabetes combination. Approval of two-drug therapy Qtern presents first-to-market advantage in Europe. ... The European Commission has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes that was turned down

  • Gilead, Merck get CHMP backing for new hep C combinations Gilead, Merck get CHMP backing for new hep C combinations

    At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes.

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics